HLB Co., Ltd. (028300.KQ)
KRW 70500.0
(-1.26%)
KRW 70500.0
(-1.26%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 109.98 Billion KRW | -12.65% |
| 2022 | 125.92 Billion KRW | 14.38% |
| 2021 | 110.09 Billion KRW | 19.29% |
| 2020 | 92.29 Billion KRW | 80.88% |
| 2019 | 51.02 Billion KRW | 43.4% |
| 2018 | 35.57 Billion KRW | 30.71% |
| 2017 | 27.21 Billion KRW | -0.47% |
| 2016 | 27.34 Billion KRW | 77.68% |
| 2015 | 15.39 Billion KRW | 150.64% |
| 2014 | 6.14 Billion KRW | -43.77% |
| 2013 | 10.92 Billion KRW | -7.06% |
| 2012 | 11.75 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 39.73 Billion KRW | 8.0% |
| 2024 Q1 | 36.79 Billion KRW | 57.51% |
| 2023 Q4 | 23.35 Billion KRW | -17.24% |
| 2023 Q2 | 27.88 Billion KRW | -2.02% |
| 2023 Q1 | 28.46 Billion KRW | 17.16% |
| 2023 Q3 | 28.22 Billion KRW | 1.21% |
| 2023 FY | 109.98 Billion KRW | -12.65% |
| 2022 Q3 | 38.98 Billion KRW | 15.3% |
| 2022 Q4 | 24.29 Billion KRW | -37.69% |
| 2022 Q2 | 33.81 Billion KRW | 17.25% |
| 2022 Q1 | 28.83 Billion KRW | -44.28% |
| 2022 FY | 125.92 Billion KRW | 14.38% |
| 2021 Q2 | 16.39 Billion KRW | -12.24% |
| 2021 Q4 | 51.75 Billion KRW | 122.44% |
| 2021 Q3 | 23.26 Billion KRW | 41.91% |
| 2021 FY | 110.09 Billion KRW | 19.29% |
| 2021 Q1 | 18.68 Billion KRW | 8.84% |
| 2020 Q4 | 17.16 Billion KRW | -12.31% |
| 2020 FY | 92.29 Billion KRW | 80.88% |
| 2020 Q2 | 48.39 Billion KRW | 228.95% |
| 2020 Q1 | 14.71 Billion KRW | -17.95% |
| 2020 Q3 | 19.57 Billion KRW | -59.56% |
| 2019 Q2 | 73.08 Billion KRW | 616.21% |
| 2019 FY | 51.02 Billion KRW | 43.4% |
| 2019 Q4 | 17.93 Billion KRW | -12.14% |
| 2019 Q3 | 20.41 Billion KRW | -72.07% |
| 2019 Q1 | 10.2 Billion KRW | -11.92% |
| 2018 Q4 | 11.58 Billion KRW | 51.96% |
| 2018 FY | 35.57 Billion KRW | 30.71% |
| 2018 Q2 | 10.02 Billion KRW | -59.93% |
| 2018 Q1 | 25.02 Billion KRW | 72.94% |
| 2018 Q3 | 7.62 Billion KRW | -23.97% |
| 2017 Q1 | 4.92 Billion KRW | -66.03% |
| 2017 FY | 27.21 Billion KRW | -0.47% |
| 2017 Q4 | 14.46 Billion KRW | 117.3% |
| 2017 Q3 | 6.65 Billion KRW | 15.03% |
| 2017 Q2 | 5.78 Billion KRW | 17.62% |
| 2016 FY | 27.34 Billion KRW | 77.68% |
| 2016 Q4 | 14.48 Billion KRW | 221.65% |
| 2016 Q3 | 4.5 Billion KRW | -0.08% |
| 2016 Q2 | 4.5 Billion KRW | 27.48% |
| 2016 Q1 | 3.53 Billion KRW | -77.14% |
| 2015 Q1 | 1.78 Billion KRW | 17.6% |
| 2015 Q4 | 15.46 Billion KRW | 355.29% |
| 2015 Q3 | 3.39 Billion KRW | 0.36% |
| 2015 Q2 | 3.38 Billion KRW | 89.87% |
| 2015 FY | 15.39 Billion KRW | 150.64% |
| 2014 Q2 | 2.17 Billion KRW | 130.42% |
| 2014 Q4 | 1.51 Billion KRW | 0.38% |
| 2014 Q1 | 942.98 Million KRW | -78.06% |
| 2014 FY | 6.14 Billion KRW | -43.77% |
| 2014 Q3 | 1.5 Billion KRW | -30.52% |
| 2013 Q1 | 2.27 Billion KRW | -32.85% |
| 2013 Q3 | 141.43 Million KRW | -96.85% |
| 2013 FY | 10.92 Billion KRW | -7.06% |
| 2013 Q4 | 4.29 Billion KRW | 2939.24% |
| 2013 Q2 | 4.49 Billion KRW | 97.87% |
| 2012 Q4 | 3.38 Billion KRW | 23.1% |
| 2012 FY | 11.75 Billion KRW | 0.0% |
| 2012 Q3 | 2.74 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| iNtRON Biotechnology, Inc. | 7.84 Billion KRW | -1301.853% |
| BINEX Co., Ltd. | 55.67 Billion KRW | -97.549% |
| Bioneer Corporation | 204.55 Billion KRW | 46.232% |
| Anterogen.Co.,Ltd. | 7.74 Billion KRW | -1320.985% |
| MEDIPOST Co., Ltd. | 65.31 Billion KRW | -68.395% |
| CrystalGenomics, Inc. | 32.36 Billion KRW | -239.781% |
| Helixmith Co., Ltd | 37.36 Billion KRW | -194.34% |
| Chabiotech Co.,Ltd. | 285.93 Billion KRW | 61.535% |
| Medy-Tox Inc. | 110.88 Billion KRW | 0.81% |
| Peptron, Inc. | 16.65 Billion KRW | -560.322% |
| Amicogen, Inc. | 52.82 Billion KRW | -108.216% |
| Genexine, Inc. | 41.62 Billion KRW | -164.212% |
| HLB Therapeutics Co.,Ltd. | 16.16 Billion KRW | -580.339% |
| LegoChem Biosciences, Inc. | 98.61 Billion KRW | -11.526% |
| ALTEOGEN Inc. | 40.93 Billion KRW | -168.684% |
| PharmaResearch Co., Ltd. | 89.44 Billion KRW | -22.972% |
| SillaJen, Inc. | 5.11 Billion KRW | -2051.44% |
| JETEMA, Co., Ltd. | 25.66 Billion KRW | -328.559% |
| OliX Pharmaceuticals,Inc | 35.24 Billion KRW | -212.023% |
| Genomictree Inc. | 16.26 Billion KRW | -576.223% |
| MedPacto, Inc. | 26.91 Billion KRW | -308.579% |
| D&D Pharmatech | 32.16 Billion KRW | -241.964% |
| EASY BIO,Inc. | 29.67 Billion KRW | -270.677% |
| GI Innovation, Inc. | 57.59 Billion KRW | -90.973% |